Faculty

Dr. Ritu Salani serves as the Director of Gynecologic Oncology at the University of California, Los Angeles (UCLA). Dr. Salani received her undergraduate degree in Integrated Life Sciences from Kent State University, Kent, Ohio. She then completed her medical degree at Northeast Ohio Medical University (NEOMED). She received her MBA from The Johns Hopkins University, Baltimore, Maryland. Dr. Salani completed her internship and residency in Gynecology and Obstetrics at Emory University School of Medicine, Atlanta, Georgia, and her fellowship in Gynecologic Oncology at The Johns Hopkins University School of Medicine. She is board-certified in Gynecologic Oncology and Obstetrics & Gynecology by the American Board of Obstetrics and Gynecology. Dr. Salani is a nationally renowned expert in the treatment of gynecologic malignancies with over 17 years of experience.

Dr. Salani’s expertise is in providing comprehensive care to patients with gynecologic malignancies with treatments including surgery and the administration of systemic treatments, such as chemotherapy, immunotherapy, novel therapies, and access to clinical trials. Her clinical care is focused on delivering compassionate care with state-of-the-art medicine and best clinical practices.

Dr. Salani has served as a Program Fellowship Director and is dedicated to the education of the next generation of healthcare providers. She has received multiple teaching awards throughout her career and focuses on innovative teaching methods.

Dr. Salani’s research focuses on clinical trials with novel therapies, best practices after cancer treatment, and improving patient-centered outcomes. She has over 150 peer-reviewed publications and is a national and international leader in the field. She is actively involved in professional societies where she’s served in a variety of leadership roles, including NRG Oncology (Cervical Cancer Committee), National Cancer Institute Gynecologic Cancer Steering Committee (Cervical Cancer Task Force Co-Chair), Society of Gynecologic Oncology (Education and Finance Committee), and the International Gynecologic Cancer Society (Education Committee Chair and Secretary-Treasurer).

Dr. Ritu Salani discloses that she is on the advisory board for Merck, Genmab, Daiichi Sankyo, Eisai, GSK, and Pfizer. All relevant financial relationships have been mitigated.